Day 3 highlights from the 23rd IMS Annual Meeting! #IMS26

Industry Symposium focused on access challenges around newer therapies & principles for optimizing treatment in the early relapse setting, for which multiple options are available, representing different drug classes, MOAs, & combinations. #IMS26

At 5:00 PM in Hall 5: Special Session with Patient Groups. #IMS26

Ph2 MILESTONE pilot trial of post-induction MRD-adapted ASCT deferral showed 42-month PFS of 83.6%, OS of 100%. Transplant deferral rate was 30% --- Susan Bal, MD. Completed MASTER-2 prospectively tested MRD-adapted ASCT deferral. #IMS26

Zachary Avigan, MD, shares a real-world analysis of sustained MRD-adapted treatment cessation & potential for cure by IMS-IMWG criteria. Among pts w/o high-risk myeloma who stopped therapy, relapse risk plateaus after 5 years. #IMS26

Leo Rasche, MD, presents first data from ongoing ph2 MajesTEC-5 trial of Tal-Dara-len induction in transplant-eligible newly diagnosed myeloma. At pre-maintenance timepoint, 90% of pts were MRD-negative @ 1/100,000. #IMS26

Interim data from ph2 IFM2022-02 trial of MRD-adapted consolidation approach show 95% conversion to MRD-negativity (NGS, @ 1/1,000,000) with Tec+ Tal in newly diagnosed pts who were MRD+ after Dara-VRd induction --- Cyrille Touzeau, MD, PhD #IMS26

Resistance to less-potent IMiDs in myeloma can be rescued with more-potent IMiDs. IMiD resistance represents both a problem and opportunity, Vidyasgar Koduri, MD, PhD, said, who spoke abt CRBN mutation-driven IMiD resistance mechanisms. #IMS26

Katja Klausz, PhD, shared preclinical proof-of-concept data for potent NK cell-engagers targeting CD38 and NKp30 as anti-myeloma therapeutic agents, including in mouse myeloma models. #IMS26

Read this Blood Cancer Discovery review by #IMS26 plenary speaker Saad Z. Usmani, “First-line Therapy in Newly Diagnosed Multiple Myeloma.” buff.ly/fQ7gatp @szusmani.bsky.social

Congratulations to Dr. Nizar Bahlis (U of Calgary) who is the 2026 recipient of the International Myeloma Society Anderson Award. A well deserved honour that reflects his impact on Myeloma care. #IMS26

At 3:00 PM in Hall 5: Plenary Session. #IMS26

We've recapped days 1 and 2 of #IMS26 @myeloma-society.bsky.social. Stay tuned for day 3!
Day 1: www.targetedonc.com/view/ims-202...
Day 2: www.targetedonc.com/view/ims-day...

Mohamad Mohty, MD, PhD, outlined areas warranting further exploration — a reproducible immune fitness score, understanding memory T-cell dynamics, & immune monitoring to predict infection risk in candidates for CAR-T/bispecifics. #IMS26

When you see improvement in overall survival with primary IVIG prophylaxis, besides reduced infection risk, this is a strategy we should adopt for T-cell redirecting therapy recipients --- Noopur Raje, MD #IMS26

Early treatment initiation is key, when it comes to managing IEC-Parkinsonism, Surbhi Sidana, MD, said. Preventing infections is crucial in patients who develop IEC-colitis, as infections are a leading cause of death in this context. #IMS26

We not only need to treat infections in T-cell redirecting therapy recipients, but also identify high-risk patients, their risk timing, & employ risk-adapt approaches, Paula Rodriguez-Otero, MD, PhD, said. #IMS26

Doris Hansen, MD, said stratification tools to help predict treatment-related toxicity risk are important for personalizing myeloma immune-based therapies. She spoke about SCOPE-MM & markers that can help predict CAR-T toxicity risk. #IMS26

In the Industry Symposium, clinicians & a patient advocate discussed treatment pathways that may lead to cure and the IMS-IMWG cure criteria, folding in QoL, long-term safety, access, time/financial toxicities, & patient perspectives. #IMS26

Meet the Experts begins at 12:00 PM. #IMS26

Choosing the optimal imaging test ➡️ Boisdale
Management of patients with extramedullary disease ➡️ Dochart
Animal models ➡️Carron